Spexis AG
Spexis is a clinical-stage biopharma focused on macrocycles for rare diseases & oncology.
ColiFin® is US Ph 3-ready for testing in chronic cystic fibrosis lung infections; developed with an equity investment by the Cystic Fibrosis Foundation. Inhaled murepavadin is in Ph 1 for chronic CF lung infections and has strong potential in non-CF bronchiectasis (nCFBE) and COPD.
Balixafortide has been in 8 clinical trials totaling >500 subjects in oncology and non-oncology and is being assessed for further clinical trials.
Spexis has a novel, proprietary macrocycle platform with extensive peptidic/non-peptidic libraries, databases & IP & has generated various clinical & preclinical compounds. The platform is expected to fuel the pipeline and create partnering opportunities.
Spexis at a glance:
| Field of Activity | Discovering and developing treatments for rare diseases and oncology, with an initial focus on chronic respiratory diseases including cystic fibrosis |
| Ownership Structure and Financing | Publicly listed on Swiss SIX stock exchange; symbol – SPEX |
| Partners | Funding for certain programs from CF Foundation, Innovative Medicines Initiative & CARB-X.
Fosun Pharma: China rights Balixafortide |
| Technology | Macrocycle platform: 2 distinct, well characterized libraries plus deep data: PEMfinder®-peptidomimetic macrocycles and MACROfinder®-small, non-peptidic molecules |
| Products/Services |
|
| Unique Selling Point | • Ph 3-ready + Ph 1 assets for CF infections • Balixafortide-oncology, hematologic and rare disease indications • Macrocycle platform for new programs and partnering |
| Date of Incorporation/ Number of Employees |
Launch of Spexis December 2021 (merger close) /27 |
Contact:
| Address | Hegenheimermattweg 125 4123 Allschwil Schweiz |
| Telephone | +41 61 567 16 00 |
| info@spexisbio.com | |
| Web Address | www.spexisbio.com |
| Social Media |